$BIIB $SPX: Biogen Stock Could Have Run Up Too Far on Alzheimer’s Drug Revival

Date: Tuesday, October 22nd, 2019

Stock(s) mentioned: ,

Source: Barron’s (https://www.barrons.com)

Summary: Shares were up as high as 37% in early trading after the biotech company seemingly erased its signal failure of the year. Some analysts are more cautious.

Full article address: https://on.barrons.com/2BApyNk

Related News:

$BIIB: UPMC Health Plan reaches deal with pharmaceutical company for …

$GILD $BIIB $XLRN $CELG $AMRN: Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

$CLOU $BIIB $CMI: 3 of 2019’s Best New ETFs to Watch

$AMGN $ALXN $BIIB $BMRN $VRTX: Buy Big Biotech — But Not Gilead, Analyst Says

$NVS $RHHBY $BIIB $PTCT: Roche’s SMA Drug Meets Primary Endpoint in Pivotal Study

$BIIB $AMGN $IBB: China seen as the next big growth area for biotechs Biogen and Amgen

$ABBV $RHHBY $JNJ $BIIB: AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL

$BIIB $CELG $BMY: Better Buy: Biogen vs. Celgene

$BIIB: Biogen’s Alzheimer’s Drug Goes From Bust to Boon, Plus Why …

$SPX $BIIB $AMGN $REGN: Biotech Funds Are Beating the Market, but Investors Are Still Bailing Out

$BIIB: Biogen expands biosimilar relationship with Bioepis

Latest News:

$TGT: Target (TGT) Q3 Earnings and Revenues Top Estimates

$SPX $WMT $MRK: Need to Know: Your three-stock survival kit for 2020, says this equity strategist

$TGT $WMT: Target Blasts Q3 Earnings Forecast, Boosts 2019 Guidance: Shares Hit Record High

$EW: Bull of the Day: Edwards Lifesciences (EW)

$MOV $FOSL: Bear of the Day: Fossil (FOSL)

$SCVL $URBN $BOOT $DECK: Urban Outfitters (URBN) Stock Declines on Q3 Earnings Miss

$TMO $PACB $NUVA $ILMN: Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates

$CNX $PSX $MCF $COP: ConocoPhillips Lays Out Plans for Next Decade, Aims $50B FCF

$NMIH: NMI Holdings Shares March Higher, Can It Continue?

$SAH $BLDR $BCC $DK $CLW: 5 Attractive Stocks Post Recent Broker Rating Upgrades

$LOW $HD: Lowe’s earnings top estimates despite revenue shortfall, raises 2019 forcast